CAMBRIDGE, Mass. (AP) _ Blueprint Medicines Corp. (BPMC) on Tuesday reported a loss of $159.7 million in its second quarter.

The Cambridge, Massachusetts-based company said it had a loss of $2.68 per share.

The results missed Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of $2.23 per share.

The cancer drug developer posted revenue of $36.5 million in the period, also falling short of Street forecasts. Nine analysts surveyed by Zacks expected $37.7 million.

Blueprint Medicines expects full-year revenue in the range of $180 million to $200 million.

Blueprint Medicines shares have dropped 53% since the beginning of the year. The stock has decreased 42% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BPMC at https://www.zacks.com/ap/BPMC

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News